Review of past and present research on experimental models of moyamoya disease

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Brain Circulation

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4103/2394-8108.166377
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Enhanced post-ischemic angiogenesis in mice lacking RNF213; a susceptibility gene for moyamoya disease.

  2015influential reference
• Smooth-muscle progenitor cells isolated from patients with moyamoya disease: novel experimental cell model.

  2014cited by this paper
• Temporal profile of the vascular anatomy evaluated by 9.4-T magnetic resonance angiography and histopathological analysis in mice lacking RNF213: a susceptibility gene for moyamoya disease.

  2014cited by this paper
• Downregulation of Securin by the variant RNF213 R4810K (rs112735431, G>A) reduces angiogenic activity of induced pluripotent stem cell-derived vascular endothelial cells from moyamoya patients.

  2013cited by this paper
• Is There a Role for Treating Inflammation in Moyamoya Disease?: A Review of Histopathology, Genetics, and Signaling Cascades

  2013cited by this paper
• The moyamoya disease susceptibility variant RNF213 R4810K (rs112735431) induces genomic instability by mitotic abnormality.

  2013cited by this paper
• Ablation of Rnf213 retards progression of diabetes in the Akita mouse.

  2013cited by this paper
• Towards the therapeutic use of vascular smooth muscle progenitor cells.

  2012cited by this paper
• Endothelial progenitor cells: a new player in lupus?

  2012cited by this paper
• Clinical and Immunopathological Features of Moyamoya Disease

  2012cited by this paper
• Increased levels of circulating SDF‐1α and CD34+ CXCR4+ cells in patients with moyamoya disease

  2011cited by this paper
• Identification of RNF213 as a Susceptibility Gene for Moyamoya Disease and Its Possible Role in Vascular Development

  2011influential reference
• Endothelial progenitor cells: novel biomarker and promising cell therapy for cardiovascular disease.

  2011cited by this paper
• A genome-wide association study identifies RNF213 as the first Moyamoya disease gene

  2011cited by this paper
• Bone marrow-derived endothelial progenitor cells participate in the initiation of moyamoya disease.

  2011cited by this paper
• Moyamoya disease: a review of histopathology, biochemistry, and genetics.

  2011cited by this paper
• A rare Asian founder polymorphism of Raptor may explain the high prevalence of Moyamoya disease among East Asians and its low prevalence among Caucasians

  2010cited by this paper
• Genetics of Moyamoya disease

  2010cited by this paper
• Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease

  2009cited by this paper
• Increased Levels of Circulating Endothelial Progenitor Cells in Patients With Moyamoya Disease

  2009cited by this paper
• Circulating Endothelial Progenitor Cells as a Pathogenetic Marker of Moyamoya Disease

  2009cited by this paper
• Pathophysiology and genetic factors in moyamoya disease.

  2009cited by this paper
• Decreased level and defective function of circulating endothelial progenitor cells in children with moyamoya disease

  2009cited by this paper
• Increase in Circulating CD34-Positive Cells in Patients with Angiographic Evidence of Moyamoya-like Vessels

  2008cited by this paper
• Moyamoya disease: current concepts and future perspectives.

  2008cited by this paper
• [Current knowledge on the genetic factors involved in moyamoya disease].

  2008cited by this paper
• EXPRESSION OF HYPOXIA‐INDUCING FACTOR‐1α AND ENDOGLIN IN INTIMAL HYPERPLASIA OF THE MIDDLE CEREBRAL ARTERY OF PATIENTS WITH MOYAMOYA DISEASE

  2007cited by this paper
• Clinical features of familial moyamoya disease

  2006cited by this paper
• Pathological and immunohistochemical findings of an autopsy case of adult moyamoya disease

  2004cited by this paper
• Increased Expression of Hepatocyte Growth Factor in Cerebrospinal Fluid and Intracranial Artery in Moyamoya Disease

  2004cited by this paper
• Experimental study of the pathogenesis of moyamoya disease: histological changes in the arterial wall caused by immunological reactions in monkeys.

  2003influential reference
• Attempt to establish an experimental animal model of moyamoya disease using immuno-embolic material-histological changes of the arterial wall resulting from immunological reaction in cats

  2003influential reference
• Elevation of CRABP-I in the Cerebrospinal Fluid of Patients With Moyamoya Disease

  2003cited by this paper
• Smooth Muscle Progenitor Cells in Human Blood

  2002cited by this paper
• Moyamoya disease and transforming growth factor-beta1.

  2000cited by this paper
• Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25.

  2000cited by this paper
• 厚生省特定疾患ウイリス動脈輪閉塞症の病因・病態に関する研究班研究報告書 = The Research committee on spontaneous occlusion of the circle of willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan annual report

  2000cited by this paper
• Increase in prostaglandin E(2) production by interleukin-1beta in arterial smooth muscle cells derived from patients with moyamoya disease.

  1999cited by this paper
• Differences in cellular responses to mitogens in arterial smooth muscle cells derived from patients with moyamoya disease.

  1998cited by this paper
• Role of basic fibroblast growth factor in the pathogenesis of moyamoya disease.

  1998cited by this paper
• Role of transforming growth factor-beta1 in the pathogenesis of moyamoya disease.

  1998cited by this paper
• The relationship between moyamoya disease and bacterial infection.

  1997cited by this paper
• Elevation of cerebrospinal fluid levels of basic fibroblast growth factor in moyamoya and central nervous system disorders.

  1997cited by this paper
• Isolation of Putative Progenitor Endothelial Cells for Angiogenesis

  1997cited by this paper
• Smooth Muscle Cell Proliferation and Localization of Macrophages and T Cells in the Occlusive Intracranial Major Arteries in Moyamoya Disease

  1993cited by this paper
• Attempts to induce immune-mediated cerebral arterial injury for an experimental model of moyamoya disease

  1992cited by this paper
• Possible roles of basic fibroblast growth factor in the pathogenesis of moyamoya disease: an immunohistochemical study.

  1991cited by this paper
• Altered cellular responses to serum mitogens, including platelet‐derived growth factor, in cultured smooth muscle cells derived from arteries of patients with moyamoya disease

  1991cited by this paper
• Platelet factor 4 and beta thromboglobulin in Moya-Moya disease.

  1984cited by this paper
• Moyamoya disease‐‐a review.

  1983cited by this paper
• [The experimental study on causal genesis of moyamoya disease - correlation with immunological reaction and sympathetic nerve influence for vascular changes (author's transl)].

  1982cited by this paper
• Experimental allergic encephalomyelitis induced by basic protein with synthetic adjuvant in comparison with Freund's complete adjuvant. Role of antibodies in correlation with the clinicopathological features.

  1981cited by this paper
• Structural Requirement of Synthetic N‐Acetylmuramyl Dipeptides for Induction of Experimental Allergic Encephalomyelitis in the Rat

  1980cited by this paper
• Cerebrovascular "Moyamoya" Disease

  1971cited by this paper
• Cerebrovascular "Moyamoya" disease. 2. Collateral routes to forebrain via ethmoid sinus and superior nasal meatus.

  1971cited by this paper
• Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain.

  1969cited by this paper
• Abnormal cerebrovascular network related to the internal cartoid arteries.

  1968cited by this paper
• Spontaneous occlusion of the circle of Willis

  1968cited by this paper
• The Application of Clinical Genetics Dovepress Moyamoya Disease and Syndromes: from Genetics to Clinical Management

  year unknowncited by this paper

• Exploring the Connection: Moyamoya Disease and Its Implications for Cardiovascular Health.

  2025cites this paper
• Common and distinct risk profiles of asymptomatic extra- and intracranial atherosclerosis in the Nagahama cohort.

  2024cites this paper
• Experimental animal models for the study of moyamoya disease.

  2021cites this paper
• Clinical Management of Moyamoya Patients

  2021cites this paper
• Experimental animal models for moyamoya disease and treatment: a pathogenesis-oriented scoping review.

  2021cites this paper
• Circular RNAs and neutrophils: Key factors in tackling asymptomatic moyamoya disease

  2019cites this paper
• Cranial burr hole with erythropoietin administration induces reverse arteriogenesis from the enriched extracranium.

  2019cites this paper
• Cerebral circulation improves with indirect bypass surgery combined with gene therapy

  2019cites this paper
• Circulating miRNome profiling in Moyamoya disease-discordant monozygotic twins and endothelial microRNA expression analysis using iPS cell line

  2018cites this paper
• Significant association of RNF213 p.R4810K, a moyamoya susceptibility variant, with coronary artery disease

  2017cites this paper
• Safety and efficacy of remote ischemic conditioning in pediatric moyamoya disease patients treated with revascularization therapy

  2017cites this paper